Cipla Limited
CIPLA
Rankning i aktier
#1816
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Aktiekurs
$14.61
Senast synkroniserad: 2026-10-19
Marknadsvärde
$11.81B
Förändring (1 dag)
-0.11%
Förändring (1 år)
-21.65%
Land
IN
Handel Cipla Limited (CIPLA)
Kategori
Healthcare
P/S-tal för Cipla Limited (CIPLA)
P/S-tal per October 2026 TTM: 3.82
Enligt Cipla Limited senaste finansiella rapporter och aktiekurs är det aktuella P/S-talet (TTM) 3.82. I slutet av 2024 hade företaget ett P/S-tal på 4.74.
Historik för P/S-tal för Cipla Limited från 2004 till 2026
P/S-tal vid årets slut
| År | P/S-tal | Ändra |
|---|---|---|
| 2026 (TTM) | 3.82 | -10.80% |
| 2025 | 4.28 | -9.65% |
| 2024 | 4.74 | 47.08% |
| 2023 | 3.22 | -14.85% |
| 2022 | 3.78 | 10.05% |
| 2021 | 3.44 | 72.27% |
| 2020 | 2.00 | -23.06% |
| 2019 | 2.59 | -15.52% |
| 2018 | 3.07 | -7.69% |
| 2017 | 3.33 | 9.59% |
| 2016 | 3.03 | -39.81% |
| 2015 | 5.04 | 86.12% |
| 2014 | 2.71 | -27.40% |
| 2013 | 3.73 | 6.94% |
| 2012 | 3.49 | -98.05% |
| 2011 | 179.33 | 3,495.17% |
| 2010 | 4.99 | 44.67% |
| 2009 | 3.45 | -19.14% |
| 2008 | 4.26 | -20.21% |
| 2007 | 5.34 | -22.03% |
| 2006 | 6.85 | 94.90% |
| 2005 | 3.52 | -7.98% |
| 2004 | 3.82 | 0.00% |
P/S-tal för liknande företag eller konkurrenter
| Företag | P/S-tal | Skillnad i P/S-tal | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | 84.88% |
IN
|
